Tides Dispatch | Jingyin Pharma Completes Full Enrollment in Phase I Clinical Trial of Novel siRNA Antithrombotic Drug SRSD107

July 11, 2024Sirius Therapeutics (SHANGHAI) Co., Ltd. ("Sirius Therapeutics") announced that the Phase I clinical trial of its self-developed small nucleic acid drug (SRSD107 injection) has recently completed dosing for all enrolled subjects. This Phase I clinical study is being conducted simultaneously in Australia and China, with preliminary data indicating that SRSD107 demonstrates good safety and tolerability, along with expected pharmacokinetic characteristics.

About Thrombosis

Thrombosis, a blood clot that restricts blood flow within blood vessels, can occur in either arterial or venous circulation and serves as the common pathological basis for most myocardial infarctions, ischemic strokes, and venous thromboembolism (VTE). Globally, one in four people die from diseases caused by thromboembolism.

About SRSD107 Injection

SRSD107 Injection is a double-stranded small interfering RNA (siRNA) drug independently developed by Sirius Therapeutics with proprietary intellectual property rights. By specifically targeting the liver-directed coagulation factor XI (FXI) mRNA, SRSD107 inhibits FXI protein expression and blocks the activation of the intrinsic coagulation pathway, thereby achieving anticoagulant/antithrombotic effects. Preclinical trial data show that a single subcutaneous injection of SRSD107 can achieve nearly 100% knockdown of FXI expression, lasting up to half a year, without any observed bleeding. With its potent, long-lasting efficacy and favorable safety profile, SRSD107 has the potential to become a first-in-class and best-in-class next-generation safer anticoagulant drug.

About Sirius Therapeutics

Sirius Therapeutics is an innovative biotechnology company dedicated to advancing human health and well-being. Focused on the development of next-generation nucleic acid therapies for cardiovascular diseases, the company aims to become a leader in transforming the prevention and treatment of chronic illnesses. Its current pipeline includes SRSD107, which is in clinical development for thromboembolic disorders, and SRDS101, aimed at treating dyslipidemia.